UNSPSC 51182303: Somatostatin

This classification denotes a hypothalmic hormone, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6E20216Q0L. European Medicines Agency schedules Somatostatin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB12320MIG. Somatostatin generally arises in the molecular formula C76H104N18O19S2.

The term SOMATOSTATIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 34, no. 10 1980, list 20.) SOMATOSTATIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule somatostatin under HS 29371900 and SITC 54154. As of Q4 2014, SOMATOSTATIN remains the US FDA Preferred Term for this commodity. Somatostatin bears US NLM identifiers UMLS ID C0037659 and NCI Concept Code C28418.

UNSPSC 51182303 Somatostatin is a Commodity code covering pharmaceutical active ingredients and finished pharmaceutical products supplied into state and local health care and correctional facilities. State and local governments procure somatostatin and related pharmaceutical products through cooperative purchasing agreements and direct RFPs, typically bundled with multi-source generic pharmaceuticals and over-the-counter products to simplify ordering, pricing, and inventory management across facility networks. The issuing bodies are primarily state healthcare procurement offices and multistate cooperative purchasing alliances that administer contracts on behalf of participating state agencies, local health departments, hospitals, and correctional systems. When a jurisdiction issues an RFP under this code, it usually seeks manufacturers willing to supply products through authorized pharmaceutical wholesalers at negotiated pricing tiers, with compliance requirements including FDA cGMP certification, Drug Supply Chain Security Act compliance, and proof of relationships with major wholesale distributors.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued an RFP in January 2026 for generic multi-source pharmaceuticals and OTC products with a response deadline of March 26, 2026. MMCAP's solicitation covers somatostatin alongside a broader pharmaceutical portfolio and involves supply through three authorized wholesalers: AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC. The RFP weights price competitiveness at 75 percent of the evaluation, with the remaining points distributed across fixed pricing, administrative compliance, EDI capability, and acceptance of a 3 percent administrative fee. Products must be available in the marketplace by May 15, 2026, with contract effectiveness on July 1, 2026. Vendors must maintain commercial general liability insurance of $5,000,000 per occurrence and comply with performance penalty provisions ranging from $200 to $1,500 per violation. The contract term is two years for new responders with optional extensions at MMCAP's discretion, and incumbent responders' amendments align through June 30, 2028.